Sugi Predict

Sugi Predict / Compounds / SCHEMBL5374444

SCHEMBL5374444

SCHEMBL5374444

CN(Cc1ccc(OCCCCOCc2ccccc2)nc1NC(=O)C(C)(C)C)C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.46
▸ GLS O94925 4/20 0.40
▸ HTR2C P28335 3/20 0.38
▸ SLC6A4 P31645 3/20 0.38
▸ PPARA Q07869 1/20 0.34
▸ FGFR1 P11362 2/20 0.33
▸ KDR P35968 2/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ NCOR2 Q9Y618 1/20 0.33
▸ AKT1 P31749 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369423 0.86 GLS (0.34) GLSHTR2CSLC6A4
SCHEMBL5372256 0.82 L3MBTL1 (0.38) L3MBTL1PPARAFGFR1KDRJAK2
SCHEMBL247076 0.78 L3MBTL1 (0.39) L3MBTL1FGFR1KDRJAK2
SCHEMBL5350756 0.77 MMP3 (0.35) L3MBTL1FGFR1KDRJAK2
SCHEMBL5379279 0.75 DRD2 (0.54) HTR2C
SCHEMBL5218290 0.75 FGFR1 (0.36) L3MBTL1FGFR1KDRJAK2
SCHEMBL5218282 0.75 FGFR1 (0.36) L3MBTL1FGFR1KDRJAK2
SCHEMBL247864 0.72 AKR1B10 (0.36) L3MBTL1FGFR1KDRJAK2
SCHEMBL16993182 0.69 L3MBTL1 (0.62) L3MBTL1HTR2CSLC6A4PPARAHDAC3
SCHEMBL22513467 0.69 MEN1 (0.51) L3MBTL1HTR2CSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160888-B2 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT COMPANY LLC (US) 2007-01-09 — — US disclosed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 — — US disclosed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 — — US disclosed
EP-1660497-A1 [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2006-05-31 — — EP disclosed
WO-2005019215-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2005-03-03 — — WO disclosed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 L3MBTL1 4010/4885GLS 743/4885HTR2C 330/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 L3MBTL1 4010/4885GLS 743/4885HTR2C 330/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 L3MBTL1 4010/4885GLS 743/4885HTR2C 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.